The weekly administration of anti-human CXCR4 antibodies to mice previously engrafted with primary AML blasts decreases the number of AML cells in the blood, BM and spleen, with minimal effects of the number of normal HSCs engrafted into NOD/SCID mice [21]. This evidence concerns the gene CXCR4 and acute myeloid leukemia.